the borders of the types of 01 lie and how early a subject can be 'classified'. It is clear that there are molecular reasons for the clinical uncertainties and that they reflect the heterogeneous nature of the causative mutations.
Two classes of mutations, those that reduce the amount of type I collagen synthesised by tissues, and those that alter the structure of the molecules made, are responsible for almost all forms of OI (fig 1) . In general, the defective synthesis mutations produce the mildest phenotypes. Mutations that alter the structure of the chains of type I procollagen and lead to the formation of abnormal molecules produce a very wide range of phenotypes, from extremely mild to lethal. Because the severity of the phenotype depends on the chain in which the mutation occurs, as well as the nature and location of the mutation, there is considerable overlap of the phenotypic entities. Molecular studies are now designed, in part, to determine how these mutations produce disease and why OI phenotypes occur in about 1 in 5000 to 1 in 10 000 subjects.
Relevant coliagen biosynthesis
To understand how mutations in collagen genes result in osteogenesis imperfecta, it helps to describe the genes and their products, and the manner in which the protein is synthesised and processed by the cell (see references 4 and 5 for more complete reviews of collagen biosynthesis and gene structure). Two genes, COLlAl located on chromosome 17 and COL1A2 located on chromosome 7, encode the proal(I) and proa2(I) chains of type I procollagen, respectively. These genes each contain more than 50 exons that contain the coding sequences for proteins of about 1400 The genes are coordinately transcribed, the mRNAs are processed and transported to the cytoplasm where they are translated on membrane bound polysomes. The precursor proteins are inserted through the membrane of the rough endoplasmic reticulum and the signal sequences are cleaved. During chain elongation, all the prolyl residues (about 100 in each chain) that precede glycine in the triple helix and some of the lysines (less than 10 in each chain) are hydroxylated by the enzymes prolyl 4- hydroxylase and lysyl hydroxylase, respectively. Some hydroxylysine residues are glycosylated and a single asparagine linked oligosaccharide is added to each chain in the carboxyl-terminal propeptide.
Each procollagen molecule contains two proal(I) chains and a single proa2(I) chain. The correct assembly of molecules is directed by interaction of the proa chains through their carboxyl-terminal globular domains. After aggregation in the 2:1 ratio the chains fold the triple helix from the carboxyl-terminal end towards the amino-terminus. The triple helix requires a glycine in every third position to fold correctly.
Although the modification by the hydroxylating and glycosylating enzymes is initiated during chain elongation, it ceases only with the formation of a stable triple helix, at which point the molecule is no longer a substrate. The completed molecule is transported out of the cell through the Golgi apparatus and deposited in the pericellular environment When an abnormal chain is included in a molecule, the translation of mutation to phenotype depends on several factors. First, almost all molecules that contain chains with mutations in the triple helical domains are less stable than their normal counterparts and are secreted less efficiently. Second, the mutation alters the structure of the mature molecule so that during processing in the rough endoplasmic reticulum the chains remain accessible to the modifying enzymes and undergo additional hydroxylation of lysyl residues in the triple helix and additional hydroxylysyl glycosylation. These molecules may have an extremely long period of residence in the rough endoplasmic reticulum (thus altering cellular architecture and perhaps other functions of the cell). Third, the abnormal molecules that leave the cell are not proteolytically processed as efficiently as the normal molecules and interfere with the normal process of fibril nucleation and growth. Fourth, abnormal fibrils are probably inefficient substrates for mineralisation. Finally, the requirements of bone for molecular structure may be greater than those of skin and other soft tissues to explain, in part, the relative tissue specificity of these mutations.
Point mutations and deletions (large or small) affect the intracellular processing of molecules in much the same way, probably because both introduce phase shifts in chain registration that reduce stability.67 72 That is, chains in these molecules become overmodified and the molecules are secreted inefficiently. As a result, the phenotypic consequences of diverse mutations are similar. There is not yet a good explanation for the effects of specific substitutions for glycyl residues in the triple helix, but the size of the substituting residue and interactions with nearby residues probably play a role in determining the phenotypic effect.
Genetics of osteogenesis imperfecta
As a result of biochemical, molecular genetic, and linkage studies there is now little question that the vast majority of subjects with OI are heterozygous for mutations in one of the genes that encode the chains of type I procollagen.45 7 74 There are rare instances of homozygosityl 65 or compound heterozygosity75
for mutations in these genes. There are also uncommon forms of OI that appear to result from mutations in non-collagen genes and are probably inherited in an autosomal recessive fashion. 6 There has been controversy about the mode of inheritance of the lethal forms of OI and of some of the deforming varieties. Some clinical studies appeared to provide evidence for autosomal recessive inheritance of lethal OI and of recessive inheritance of the progressive deforming varieties of OI.77 More recent clinical studies78 and biochemical and molecular evidence73 have now made it clear that the lethal form of OI almost always results from heterozygosity for mutations in one of the genes of type I collagen (uniparental disomy for an exon skipping mutation provides a remarkable exception, especially as the mutation results in inefficient exon removal46).
Biochemical studies, and some molecular studies, provide the same conclusion for deforming varieties of OI.21-23 Despite the molecular evidence of heterozygosity for dominant mutations, recurrence of these phenotypes among sibs born to phenotypically normal parents is not rare. Indeed, for OI type II, the sib recurrence rate is about 6%.
The modest recurrence risk for 01 type II is explained by parental gonadal, and usually somatic, mosaicism in the vast majority of such families.32 The low recurrence risk for 01 type III is probably explained by two different mechanisms: parental mosaicism and rare instances of autosomal recessive inheritance, possibly involving non-collagen genes.
The rate of parental mosaicism for collagen gene mutations seems high when compared to other disorders, but comparable studies in other genes have not been completed.
Mutation mechanisms
Collagen genes are probably good reporters of mutations. First, there is a high density of invariant and required glycine residues in the triple helical domain (one-third of all amino acids). Substitution for either of the first two nucleotides of the glycine codon (GGN) changes the amino acid. Thus 22% (two out of nine) of all nucleotides encoding the triple helical domain will probably give rise to a phenotypic change in the heterozygote. Second, the large exon number and sensitivity to exon loss in the protein provides more than 100 additional mutation sensitive sites in each gene. Third, the need to maintain structure in the globular carboxyl-terminal domain to allow for interactions that generate a triple chain molecule provides an unknown number of additional targets. Finally, because type I collagen forms fibrils from identical subunits, appearance of any abnormal molecules interferes with the production of normal structure.
The majority of mutations in collagen genes that produce recognisable forms of OI are point mutations, most of which change a glycine codon to that for another amino acid. 
